Oral administration of CU06-1004 attenuates vascular permeability and stabilizes neovascularization in retinal vascular diseases

Medicine and Dentistry

• Vascular Disease 100%
• Diseases 75%
• Oral Drug Administration 75%
• Therapeutic Procedure 75%
• Vasculotropin 50%
• Serositis 25%
• Combination Therapy 25%
• Side Effect 25%
• Angiogenesis 25%
• Endothelial Dysfunction 25%
• Endothelial Cell 25%
• Therapeutic Agent 25%
• Blood Vessel Permeability 25%
• Laser-Induced Choroidal Neovascularization 25%
• Oxygen-Induced Retinopathy 25%
• Diabetic Retinopathy 25%
• Steroid 25%
• Retinal Blood Vessel 25%
• Angiopoietin 2 25%
• Pathological Process 25%
• Vasculotropin C 25%
• Low Level Laser Therapy 25%
• Hypoxia Signalling 25%
• Injection 25%
• Vascular Occlusion 25%
• Amaurosis 25%
• Pathology 25%